Ho Khai-Linh V, Chow George K
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.
J Endourol. 2005 Sep;19(7):841-8. doi: 10.1089/end.2005.19.841.
Technological advances have increased the applicability of endoscopic treatment for upper-tract transitional-cell carcinoma (TCC). Percutaneous and ureteroscopic tumor resection have become reasonable treatment options for patients with anatomically or functionally solitary kidneys, bilateral upper-tract tumors, significant renal insufficiency, or comorbid disease that would preclude standard open surgery. This approach also is being used increasingly on those with a normal contralateral kidney in whom nephroureterectomy and en bloc removal of the ipsilateral ureteral orifice and surrounding bladder cuff is considered the standard therapy. This paper reviews the current role of ureteroscopic management of upper-tract TCC.
技术进步提高了内镜治疗上尿路移行细胞癌(TCC)的适用性。经皮和输尿管镜肿瘤切除术已成为解剖学或功能上孤立肾、双侧上尿路肿瘤、严重肾功能不全或存在合并症而不能进行标准开放手术患者的合理治疗选择。对于对侧肾脏正常但标准治疗为肾输尿管切除术及整块切除同侧输尿管口和周围膀胱袖口组织的患者,这种方法的应用也越来越多。本文综述了输尿管镜治疗上尿路TCC的当前作用。